Current Landscape
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have transformed NSCLC treatment. First-line pembrolizumab monotherapy is now standard for tumours with PD-L1 expression ≥50%.
Combination Strategies
Chemo-immunotherapy combinations show improved outcomes across PD-L1 expression levels. The KEYNOTE-189 regimen (pembrolizumab + platinum-pemetrexed) remains a standard for non-squamous NSCLC.